Market Closed -
Nasdaq
04:00:00 2024-06-10 pm EDT
5-day change
1st Jan Change
1,002
USD
-0.12%
+1.24%
+14.05%
Sales 2024 *
13.82B
Sales 2025 *
14.94B
Capitalization
108B
Net income 2024 *
3.97B
Net income 2025 *
4.42B
EV / Sales 2024 *
7.16
x
Net cash position
2024
*
9.08B
Net cash position
2025
*
14.86B
EV / Sales 2025 *
6.24
x P/E ratio 2024 *
29.6
x
P/E ratio 2025 *
26.5
x
Employees
13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float
78.42%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
Jun. 10
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
Jun. 05
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM
Jun. 05
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185
Jun. 04
MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
Jun. 03
MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK
Jun. 03
DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials
Jun. 03
CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
May. 31
RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee
May. 31
MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
May. 31
MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
May. 31
DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD
May. 31
CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation
May. 31
CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing
May. 29
MT
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
May. 23
MT
More news
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
Jun. 10
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
Jun. 05
MT
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185
Jun. 04
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing
May. 29
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing
May. 22
MT
More recommendations
1 day -0.12%
1 week +1.24%
Current month +2.20%
1 month +2.87%
3 months +3.40%
6 months +19.23%
Current year +14.05%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
53
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
83
91-05-31
More insiders
Date
Price
Change
Volume
24-06-10
1,002
-0.12%
250,886
24-06-07
1,003
+0.22%
250,100
24-06-06
1,001
-0.51%
439,791
24-06-05
1,006
+1.27%
385,583
24-06-04
993.3
+0.39%
340,445
Delayed Quote
Nasdaq, June 10, 2024 at 04:00 pm EDT
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
1,002
USD
Average target price
1,043
USD
Spread / Average Target
+4.12%
Consensus
1st Jan change
Capi.
+14.05% 108B +18.77% 125B -7.16% 23.64B +2.07% 22.39B -10.79% 17.78B -41.74% 16.43B -13.47% 16.34B +2.23% 13.56B +27.13% 11.59B +93.29% 9.66B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1